A pivotal phase II trial investigating the efficacy of OTX-101 in patients with keratoconjunctivitis sicca (dry eye disease)

Trial Profile

A pivotal phase II trial investigating the efficacy of OTX-101 in patients with keratoconjunctivitis sicca (dry eye disease)

Planning
Phase of Trial: Phase III

Latest Information Update: 20 Nov 2015

At a glance

  • Drugs OTX 101 (Primary)
  • Indications Keratoconjunctivitis sicca
  • Focus Registrational; Therapeutic Use
  • Sponsors Auven Therapeutics
  • Most Recent Events

    • 20 Nov 2015 New trial record
    • 13 Nov 2015 According to an Auven Therapeutics media release, the company expects to begin enrollment in this trial in early 2016. If this results of this study are positive, the company expects to submit an NDA for OTX-101 [Seciera] for the treatment of dry eye disease in early 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top